Chikungunya virus: recent advances in epidemiology, host pathogen interaction & vaccine strategies (original) (raw)

Abstract

The Chikungunya virus is a re-emerging alphavirus that belongs to family Togaviridae. The symptoms include fever, rashes, nausea and joint pain that may last for months. The laboratory diagnosis of the infection is based on the serologic assays, virus isolation and molecular methods. The pathogenesis of the Chikungunya viral infection is not completely understood. Some of the recent investigations have provided information on replication of the virus in various cells and organs. In addition, some recent reports have indicated that the severity of disease is correlated with the viral load and cytokines.The Chikungunya virus infection re-emerged as an explosive epidemic during 2004-09 affecting millions of people in the Indian Ocean. Subsequent global attention was given to research on this viral pathogen due to its broad area of geographical distribution during this epidemic. Chikungunya viral infection has become a challenge for the public health system because of absence of a vacci...

Loading...

Loading Preview

Sorry, preview is currently unavailable. You can download the paper by clicking the button above.

References (107)

  1. Abere B, Wikan N, Ubol S et al. Proteomic analysis of chikun- gunya virus infected microgial cells. PLoS One 2012;7:e34800.
  2. Afreen N, Deeba F, Khan WH et al. Molecular characterization of dengue and chikungunya virus strains circulating in New Delhi, India. Microbiol Immunol 2014;58:688-96.
  3. Akahata W, Yang ZY, Andersen H et al. A virus like par- ticle vaccine for epidemic chikungunya virus protects nonhuman primates against infection. Nat Med 2010;16: 334-8.
  4. Apandi Y, Nazni WA, Noor Azleen ZA et al. The first isolation of chikungunya virus from nonhuman primates in Malaysia. J Gen Mol Virol 2009;1:035-9.
  5. Arankalle VA, Shrivastava S, Cherian S et al. Genetic divergence of Chikungunya viruses in India (1963-2006) with special reference to the 2005-2006 explosive epidemic. J Gen Virol 2007;88:1967-76.
  6. Bhatia R, Narain JP. Re-emerging chikungunya fever: some lessons from Asia. Trop Med Int Health 2009;14:940-6.
  7. Borgherini G, Poubeau P, Staikowsky F et al. Outbreak of chikun- gunya on Reunion Island: early clinical and laboratory fea- tures in 157 adult patients. Clin Infect Dis 2007;44:1401-7.
  8. Brehin AC, Rubrecht L, Sanchez MEN et al. Production and characterization of mouse monoclonal antibodies reac- tive to Chikungunya envelope E2 glycoprotein. Virology 2008;371:185-95.
  9. Briolant S, Garin D, Scaramozzino N et al. In vitro inhibition of Chikungunya and Semliki Forest viruses replication by an- tiviral compounds: synergistic effect of interferon-α and rib- avirin combination. Antiviral Res 2004;61:111-7.
  10. Burke DS, Nisalak A, Nimmannitya S. Disappearance of Chikun- gunya virus from Bangkok. Trans R Soc Trop Med Hyg 1985;79:419-20.
  11. Caglioti C, Lalle E, Castilletti C et al. Chikungunya virus infection: an overview. New Microbiol 2013;36:211-27.
  12. Cavrini F, Gaibani P, Pierro AM et al. Chikungunya: an emerg- ing and spreading arthropod-borne viral disease. J Infect Dev Ctries 2009;3:744-52.
  13. Chang L-J, Dowd KA, Mendoza FH et al. Safety and tolerability of chikungunya virus-like particle vaccine in healthy adults: a phase 1 dose-escalation trial. Lancet 2014;384:2046-52.
  14. Cherian SS, Walimbe AM, Jadhav SM et al. Evolutionary rates and timescale comparison of Chikungunya viruses inferred from the whole genome/E1 gene with special reference to the 2005-07 outbreak in the Indian subcontinent. Infect Genet Evol 2009;9:16-23.
  15. Chopra A, Saluja M, Venugopalan A. Effectiveness of chloro- quine and inflammatory cytokine response in patients with early persistent musculoskeletal pain and arthritis follow- ing chikungunya virus infection. Arthritis Rheumatol 2014;66: 319-26.
  16. Chow A, Her Z, Ong EKS et al. Persistent arthralgia induced by Chikungunya virus infection is associated with interleukin- 6 and granulocyte macrophage colony-stimulating factor. J Infec Dis 2011;203:149-57.
  17. Couderc T, Chretien F, Schilte C et al. A mouse model for chikun- gunya: young age and inefficient type-I interferon signaling are risk factors for severe disease. PLoS Pathog 2008;4:e29.
  18. Cronstein BN. Interleukin-6-a key mediator of systemic and lo- cal symptoms in rheumatoid arthritis. Bull NYU Hosp Jt Dis 2007;65:S11-5.
  19. Dash PK, Tiwari M, Santhosh SR et al. RNA interference mediated inhibition of Chikungunya virus replication in mammalian cells. Biochem Biophys Res Commun 2008;376:718-22.
  20. Delang L, Segura Guerrero N, Tas A et al. Mutations in the chikungunya virus non-structural proteins cause resistance to favipiravir (T-705), a broad-spectrum antiviral. J Antimicrob Chemother 2014;69:2770-84.
  21. Deshmane SL, Kremlev S, Amini S et al. Monocyte chemoattrac- tant protein-1 (MCP-1): an overview. J Interferon Cytokine Res 2009;29:313-26.
  22. Dupuis-Maguiraga L, Noret M, Brun S et al. Chikungunya dis- ease: infection-associated markers from the acute to the chronic phase of arbovirus-induced arthralgia. PLoS Negl Trop Dis 2012;6:e1446.
  23. Eckels KH, Harrison VR, Hetrick FM. Chikungunya virus vac- cine prepared by a Tween-ether extraction. Appl Microbiol 1970;19:321-5.
  24. Edelman R, Tacket CO, Wasserman SS et al. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI- GSD-218. Am J Trop Med Hyg 2000;62:681-5.
  25. Edwards CJ, Welch SR, Chamberlain J et al. Molecular diagnosis and analysis of Chikungunya virus. J Clin Virol 2007;39:271-5.
  26. Erasmus JH, Needham J, Raychaudhuri S et al. Utilization of an Eilat virus-based chimera for serological detection of chikun- gunya infection. PLoS Negl Trop Dis 2015;9:e0004119.
  27. Garcia-Arriaza J, Cepeda V, Hallengard D et al. A novel poxvirus-based vaccine (MVA-CHIKV) is highly immuno- genic and protects mice against chikungunya infection. J Vi- rol 2014;88:3527-47.
  28. Gardner J, Anraku I, Le TT et al. Chikungunya virus arthritis in adult wild-type mice. J Virol 2010;84:8021-32.
  29. Gorchakov R, Wang E, Leal G et al. Attenuation of Chikungunya virus vaccine strain 181/clone 25 is determined by two amino acid substitutions in the E2 envelope glycoprotein. J Virol 2012;86:6084-96.
  30. Hammon WM, Rudnick A, Sather GE. Viruses associated with epidemic hemorrhagic fevers of the Philippines and Thai- land. Science 1960;131:1102-3.
  31. Harrison VR, Eckels KH, Bartelloni PJ et al. Production and eval- uation of a formalin-killed Chikungunya vaccine. J Immunol 1971;107:643-7.
  32. Hirano T, Taga T, Nakano N et al. Purification to homogeneity and characterization of human B-cell differentiation factor (BCDF or BSFp-2). Proc Natl Acad Sci USA 1985;82:5490-4.
  33. Hoarau JJ, Jaffar Bandjee MC, Krejbich Trotot P. Persistent chronic inflammation and infection by Chikungunya arthritogenic alphavirus in spite of a robust host immune response. J Im- munol 2010;184:5914-27.
  34. Jupp PG, McIntosh BM. Chikungunya disease. In: Monath TP (ed.). The Arboviruses: Epidemiology and Ecology. Boca Raton Florida: CRC Press, 1988, 137-57.
  35. Kam YW, Simarmata D, Chow A et al. Early appearance of neu- tralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and long-term clinical protec- tion. J Infec Dis 2012;205:1147-54.
  36. Kawano Y, Noma T, Yata J. Regulation of human IgG subclass production by cytokines. IFN-gamma and IL-6 act antagonis- tically in the induction of human IgG1 but additively in the induction of IgG2. J Immunol 1994;153:4948-58.
  37. Kelvin AA, Banner D, Silvi G et al. Inflammatory cytokine expres- sion is associated with chikungunya virus resolution and symptom severity. PLoS Negl Trop Dis 2011;5:e1279.
  38. Kumar M, Sudeep AB, Arankalle VA. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vac- cines against chikungunya virus. Vaccine 2012a;30:6142-9.
  39. Kumar S, Jaffer-Bandjee MC, Giry C et al. Mouse macrophage in- nate immune response to chikungunya virus infection. Virol J 2012b;9:313.
  40. Lalitha P, Rathinam S, Banushree K et al. Ocular involvement as- sociated with an epidemic outbreak of Chikungunya virus in- fection. Am J Ophthalmol 2007;144:552-6.
  41. Lam SK, Chua KB, Hooi PS et al. Chikungunya infection-an emerging disease in Malaysia. Southeast Asian J Trop Med Pub- lic Health 2001;32:447-51.
  42. Lanciotti RS, Kosoy OL, Laven JJ et al. Chikungunya virus in US travelers returning from India, 2006. Emerg Infect Dis 2007;13:764-7.
  43. Laras K, Sukri NC, Larasati RP et al. Tracking the re-emergence of epidemic chikungunya virus in Indonesia. Trans R Soc Trop Med Hyg 2005;99:128-41.
  44. Levitt NH, Ramsburg HH, Hasty SE et al. Development of an at- tenuated strain of chikungunya virus for use in vaccine pro- duction. Vaccine 1986;4:157-62.
  45. Lumsden WH. An epidemic of virus disease in southern province, Tanganyika Territory, in 1952-53. II. General de- scription and epidemiology. Trans R Soc Trop Med Hyg 1955;49:33-57.
  46. Mallilankaraman K, Shedlock DJ, Bao H et al. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl Trop Dis 2011;5:e928.
  47. Malvy D, Ezzedine K, Mamani-Matsuda M et al. Destructive arthritis in a patient with chikungunya virus infection with persistent specific IgM antibodies. BMC Infect Dis 2009;9:200.
  48. Manimunda SP, Singh SS, Sugunan AP et al. Chikungunya fever, Andaman and Nicobar Islands, India. Emerg Infect Dis 2007;13:1259-60.
  49. Manimunda SP, Vijayachari P, Uppoor R et al. Clinical pro- gression of chikungunya fever during acute and chronic arthritic stages and the changes in joint morphology as re- vealed by imaging. Trans R Soc of Trop Med Hyg 2010;104: 392-9.
  50. Metz SW, Gardner J, Geertsema C et al. Effective chikungunya virus-like particle vaccine produced in insect cells. PLoS Negl Trop Dis 2013;7:e2124.
  51. Mittal A, Mittal S, Bharati MJ et al. Optic neuritis associated with chikungunya virus infection in South India. Arch Ophthalmol 2007;125:1381-6.
  52. Muthumania K, Lankaraman KM, Laddy DJ et al. Immunogenic- ity of novel consensus-based DNA vaccines against Chikun- gunya virus. Vaccine 2008;26:5128-34.
  53. Muyembe-Tamfum JJ, Peyrefitte CN, Yogolelo R et al. Epidemic of Chikungunya virus in 1999 and 2000 in the Democratic Re- public of the Congo. Med Trop (Mars) 2003;63:637-8.
  54. Neogi DK, Bhattacharya N, Mukherjee KK et al. Serosurvey of chikungunya antibody in Calcutta metropolis. J Commun Dis 1995;27:19-22.
  55. Ng LFP, Chow A, Sun YJ et al. IL-1β, IL-6, and RANTES as biomarkers of Chikungunya severity. PLoS One 2009;4: e4261.
  56. Niyas KP, Abraham R, Unnikrishnan RN et al. Molecular charac- terization of Chikungunya virus isolates from clinical sam- ples and adult Aedes albopictus mosquitoes emerged from lar- vae from Kerala, South India. Virol J 2010;7:189.
  57. Obeyesekere I, Hermon Y. Arbovirus heart disease: Myocardi- tis and cardiomyopathy following dengue and chikun- gunya fever-A follow-up study. Am Heart J 1973;85: 186-94.
  58. Ozden S, Huerre M, Riviere J-P et al. Human muscle satellite cells as targets of Chikungunya virus infection. PLoS One 2007;6:e527.
  59. Padbidri VS, Gnaneswar TT. Epidemiological investigations of Chikungunya epidemic at Barsi, Maharashtra State, India. J Hyg Epidemiol Microbiol Immunol 1979;23:445-51.
  60. Parashar D, Paingankar MS, Kumar S et al. Administration of E2 and NS1 siRNAs inhibit chikungunya virus replication in- vitro and protects mice infected with the virus. PLoS Negl Trop Dis 2013;7:e2405.
  61. Parola P, de Lamballerie X, Jourdan J et al. Novel chikungunya virus variant in travelers returning from Indian Ocean is- lands. Emerg Infect Dis 2006;12:1493-99.
  62. Pastorino B, Muyembe-Tamfum JJ, Bessaud M et al. Epidemic resurgence of Chikungunya virus in Democratic Republic of the Congo: Identification of a new central African strain. J Med Virol 2004;74:277-82.
  63. Peyrefitte CN, Rousset D, Pastorino BAM et al. Chikungunya virus, Cameroon. Emerg Infect Dis 2007;13:5.
  64. Pialoux G, Gauzere BA, Jaureguiberry S et al. Chikungunya, an epidemic arbovirosis. Lancet Infect Dis 2007;7:319-27.
  65. Plante K, Wang E, Partidos CD et al. Novel Chikungunya vaccine candidate with an IRES-based attenuation and host range al- teration mechanism. PLoS Pathog 2011;7:e1002142.
  66. Powers AM, Brault AC, Tesh RB et al. Re-emergence of chikun- gunya and o'nyong-nyong viruses: evidence for distinct ge- ographical lineages and distant evolutionary relationships. J Gen Virol 2000;8:471-9.
  67. Powers AM, Logue CH. Changing patterns of chikungunya virus: reemergence of a zoonotic arbovirus. J Gen Virol 2007;88: 2363-77.
  68. Qin S, Rottman JB, Myers P et al. The chemokine receptors CXCR3 and CCR5 mark subsets of T cells associated with certain in- flammatory reactions. J Clin Invest 1998;101:746-54.
  69. Quatresous I. E-alert27 January: Chikungunya outbreak in Reunion, a French Overseas Department. Eurosurveillance Weekly 2006;11:E060202.
  70. Rao TR. Recent epidemics caused by Chikungunya virus in India, 1963-1965. Sci Cult 1966;32:215-20.
  71. Ravi V. Re-emergence of Chikungunya virus in India. Indian J Med Microbiol 2006;24:83-4.
  72. Renault P, Solet JL, Sissoko D et al. A major epidemic of Chikun- gunya virus infection on Reunion Island, France, 2005-2006. Am J Trop Med Hyg 2007;77:727-31.
  73. Robin S, Ramful D, Zettor J et al. Severe bullous skin lesions as- sociated with chikungunya virus infection in small infants. Eur J Pediatr 2009;169:67-72.
  74. Robinson M. An epidemic of virus disease in southern province, Tanganyika Territory, in 1952-53. I. Trans R Soc Trop Med Hyg 1955;49:28-32.
  75. Rodrigues FM, Patankar MR, Banerjee K et al. Etiology of the1965 epidemic of febrile illness in Nagpur city, Maharashtra State, India. Bull World Health Organ 1972;46:173-9.
  76. Rot A, von Andrian UH. Chemokines in innate and adaptive host defense: basic chemokinese grammar for immune cells. Annu Rev Immunol 2004;22:891-928.
  77. Rothan HA, Bahrani H, Mohamed Z et al. A combination of doxy- cycline and ribavirin alleviated chikungunya infection. One 2015;10:e0126360.
  78. Rulli NE, Rolph MS, Srikiatkhachorn A et al. Protection from arthritis and myositis in a mouse model of acute chikun- gunya virus disease by bindarit, an inhibitor of monocyte chemotactic protein-1 synthesis. J Infec Dis 2011;204:1026-30.
  79. Sahu A, Das B, Das M et al. Genetic characterization of E2 re- gion of Chikungunya virus circulating in Odisha, Eastern In- dia from 2010 to 2011. Infect Genet Evol 2013;18:113-24.
  80. Sam IC, AbuBakar S. Chikungunya virus infection. Med J Malaysia 2006;61:264-9.
  81. Santhosh SR, Dash PK, Parida MM et al. Comparative full genome analysis revealed E1: A226V shift in 2007 Indian Chikungunya virus isolates. Virus Res 2008;135:36-41.
  82. Schaible HG, von Banchet GS, Boettger MK et al. The role of proin- flammatory cytokines in the generation and maintenance of joint pain. Ann N Y Acad Sci 2010;1193:60-9.
  83. Schilte C, Staikovsky F, Couderc T et al. Chikungunya virus- associated long-term arthralgia: A 36-month prospective longitudinal study. PLoS Negl Trop Dis 2013;7:e2137.
  84. Schuffenecker I, Iteman I, Michault A et al. Genome microevolu- tion of chikungunya viruses causing the Indian Ocean out- break. PLoS Med 2006;3:e263.
  85. Schwartz O, Albert ML. Biology and pathogenesis of Chikun- gunya virus. Nat Rev 2010;8:491-500.
  86. Sergon K, Njuguna C, Kalani R et al. Seroprevalence of Chikun- gunya virus (CHIKV) infection on Lamu Island, Kenya, Octo- ber 2004. Am J Trop Med Hyg 2008;78:333-7.
  87. Shah KV, Gibbs CJ, Banerjee G. Virological investigation of the epidemic of haemorrhagic fever in Calcutta: isolation of three strains of chikungunya virus. Indian J Med Res 1964;52:676-83.
  88. Shrinet J, Jain S, Sharma A et al. Genetic characterization of Chikungunya virus from New Delhi reveal emergence of a new molecular signature in Indian isolates. Virol J 2012;9:100.
  89. Singh P, Chhabra M, Mittal V et al. Current research and clinical trials for a vaccine against Chikungunya virus. Vaccine (Auckl) 2013;3:35-46.
  90. Singh P, Mittal V, Rizvi MMA et al. The first dominant co- circulation of both dengue and chikungunya viruses during the post-monsoon period of 2010 in Delhi, India. Epidemiol Infect 2010;140:1337-42.
  91. Solignat M, Gay B, Higgs S et al. Replication cycle of chikungunya: A re-emerging arbovirus. Virology 2009;393:183-97.
  92. Sreekumar E, Issac A, Nair S et al. Genetic characterization of 2006-2008 isolates of Chikungunya virus from Kerala, South India, by whole genome sequence analysis. Virus Genes 2010;40:14-27.
  93. Talarmin F, Staikowsky F, Schoenlaub P et al. Skin and mucosal manifestations of chikungunya virus infection in adults in Reunion Island. Med Trop (Mars) 2007;67:167-73.
  94. Thaung U, Ming CK, Swe T et al. Epidemiological features of dengue and chikungunya infections in Burma. Southeast Asian J Trop Med Public Health 1975;6:276-83.
  95. Thonnon J, Spiegel A, Diallo M et al. Chikungunya virus outbreak in Senegal in 1996 and 1997. Bull Soc Pathol Exot 1999;92:79-82.
  96. Tiwari M, Parida M, Santhosh SR et al. Assessment of immuno- genic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine 2009;27:2513-22.
  97. Tsetsarkin KA, Vanlandingham DL, McGee CE et al. A single mu- tation in Chikungunya virus affects vector specificity and epidemic potential. PLoS Pathog 2007;3:e201.
  98. Vashishtha M, Phalen T, Marquardt MT et al. A single point mu- tation controls the cholesterol dependence of Semliki Forest virus entry and exit. J Cell Biol 1998;140:91-9.
  99. Vazeille M, Moutailler S, Coudrier D et al. Two Chikungunya iso- lates from the outbreak of La Reunion (Indian Ocean) exhibit different patterns of infection in the mosquito, Aedes albopic- tus. PLoS One 2007;11:e1168.
  100. Volk SM, Chen R, Tsetsarkin KA et al. Genome-scale phylogenetic analyses of chikungunya virus reveal independent emer- gences of recent epidemics and various evolutionary rates. J Virol 2010;84:6497.
  101. Wang D, Suhrbier A, Penn-Nicholson A et al. A complex ade- novirus vaccine against chikungunya virus provides com- plete protection against viraemia and arthritis. Vaccine 2011;29:2803-9.
  102. Wanga E, Volkovac E, Adams AP et al. Chimeric alphavirus vac- cine candidates for Chikungunya. Vaccine 2008;26:5030-9.
  103. Warter L, Lee CY, Thiagarajan R et al. Chikungunya virus envelope-specific human monoclonal antibodies with broad neutralization potency. J Immunol 2011;186:3258-64.
  104. Wauquier N, Becquart P, Nkoghe D et al. The acute phase of chikungunya virus infection in humans is associated with strong innate immunity and T CD8 cell activation. J Infec Dis 2011;204:115-23.
  105. Weaver SC, Forrester NL. Chikungunya: Evolutionary history and recent epidemic spread. Antiviral Res 2015;120:32-9.
  106. Weaver SC, Frey TK, Huang HV et al. Togaviridae. In: Fauquet CM, Mayo MA, Maniloff J, Desselberger U, Ball LA (eds). Virus Tax- onomy: Eighth Report of the International Committee on Taxonomy of Viruses. San Diego, CA, USA, London: Elsevier Academic Press, 2005, 999-1008.
  107. Yergolkar PN, Tandale BV, Arankalle VA et al. Chikungunya out- breaks caused by African genotype, India. Emerg Infect Dis 2006;12:1580-3.